Le Lézard10h
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences
POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the addition of a new ...
IGC Pharma, Inc.: IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences
POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the ad ...
Medscape15h
When to Consider Cannabinoid Hyperemesis Syndrome in T1D
In patients with T1D, cannabinoid hyperemesis syndrome and diabetic gastroparesis have similar symptoms but different ...